Psoriatic Arthritis

New Phase 3 trial results reveal deucravacitinib's effectiveness in treating active psoriatic arthritis, offering hope for improved patient outcomes.

New research highlights deucravacitinib's effectiveness in alleviating both skin and joint symptoms in people with both psoriasis and psoriatic arthritis.

Patients with concurrent type 2 diabetes mellitus and psoriatic arthritis who have a BMI below 30 kg/m2 exhibit higher all-cause mortality and lower 5-year survivability than those with higher BMI measurements.

Intensive DMARD treatments significantly reduce pain in rheumatoid and psoriatic arthritis, shifting focus from opioids to effective pain management strategies.

New findings reveal that psoriatic arthritis symptoms often appear before psoriasis, challenging traditional beliefs about their development sequence.

Celltrion's Yuflyma gains FDA interchangeability, offering a cost-effective biosimilar option for various conditions, including rheumatoid arthritis and psoriasis.

SELARSDI gains FDA interchangeability with Stelara, enhancing access to affordable treatments for psoriatic arthritis, psoriasis, Crohn's, and ulcerative colitis.

These data suggest promise for dietary interventions and anti-obesity therapies such as incretin-based weight loss medicines for those with psoriatic arthritis (PsA).

3-year interim analysis of the SERENA study confirmed the safety of secukinumab to treat psoriatic arthritis and ankylosing spondylitis.

Findings suggest MetS is linked to greater levels of pain catastrophizing in psoriatic arthritis, highlighting the need for multidisciplinary care.

Tumor necrosis factor-α inhibitors are suggested as the optimal treatment for both joint and skin symptoms.

Investigators call for faster diagnosis and better treatment for psoriatic arthritis to avoid unnecessary complication and suffering.

Anti-IL-17 medications meant to treat psoriasis and psoriatic arthritis may inadvertently harm gastrointestinal tract.

hsCRP may be a more accessible and reliable method of indicating inflammation, a known precursor to PsA.

Small but significant decreases were also seen in depression and anxiety scores in people with and without psoriatic arthritis.

Hazard ratios of MACE were similar between patients treated with ustekinumab, adalimumab, etanercept, and secukinumab.

Data from the POETYK PsA-2 trial examining deucravacitinib were presented at the 2025 American Academy of Dermatology annual meeting.

Golimumab, marketed under the names Simponi and Simponi Aria, is approved for RA, PsA, AS, and UC.

Delphi exercises revealed concordance between prioritized areas but also notable differences.

Infection and injury were the most common responsible diagnoses for patinets with both PsA or AS.

Cancer risk was examined for breast, colorectal, lung, and prostate cancer.

Small molecule drugs may help fill gaps in treatment with biologic therapies.

A recent study identified the prevalence of asymptomatic pulmonary involvement in patients with newly diagnosed RA or PsA, highlighting the need to reevaluate screening protocols.

After 16 weeks of treatment, a significantly greater proportion of deucravacitinib-treated patients achieved ACR20 response.